Pharmaceuticals

Facing delisting for being a 'public shell,' XTL Biopharma plans an appeal while its new acquisition and valuable IP hang in the balance.

As Cipla rolls out its affordable Liraglutide injection, the battle for the multi-billion dollar GLP-1 market intensifies, promising greater access for patients.

The stars join The Elizabeth Taylor AIDS Foundation to modernize laws from the '80s that criminalize HIV status, clashing with modern science.

As Canada prepares for generic Semaglutide, U.S. patients look north for relief from soaring drug costs, navigating a complex web of savings and risks.

On Rare Disease Day, Polaryx Therapeutics advances a novel oral drug in a pivotal trial for four devastating pediatric disorders, offering a new strategy.

A new emergency epilepsy medication for children is now available, offering a faster, easier-to-use option for caregivers to stop prolonged seizures.

A key European panel recommends Dupixent for children with chronic hives, offering a potential first-of-its-kind targeted therapy for a difficult condition.

A new oral therapy, mavorixafor, receives a key recommendation in Europe, offering a beacon of hope for patients with a debilitating ultra-rare immune disorder.

The Mexican pharma giant saw sales fall in 2025 but improved margins, strategically clearing inventory and reinvesting savings for a planned 2026 recovery.

With its Healthcare Services platform growing, SelectQuote executives will face investors to detail their tech-driven strategy amid market pressures.

Tectonic Therapeutic reports key clinical progress in two distinct rare diseases, backed by a strong cash position and new leadership for its next phase.

Neurizon Therapeutics has started dosing its promising ALS drug, NUZ-001, in the groundbreaking HEALEY Platform Trial, a pivotal step for patients.

With Phase 3 epilepsy results for its lead drug azetukalner due in March, Xenon reveals a major R&D spend and a cash runway to fuel its broad pipeline.

With clinical results converging, a new report reveals the real GLP-1 battle is fought in patent filings, not labs, deciding who wins this $100B+ market.

Amid new regulations, eClinical Solutions unveils agentic AI to automate data review, streamline compliance, and accelerate breakthrough therapies.

Biotech giant Regeneron extends its sponsorship of America's top high school science contest, securing its legacy and boosting access for a new generation.

A new partnership integrates massive clinical trial data with an AI design platform, promising to slash drug development timelines and costs. Here's how.

A new global alliance aims to solve the costly patient adherence problem by merging world-class marketing with a proven, AI-powered digital health platform.

Sarepta will unveil crucial long-term data for its Duchenne gene therapy and exon-skipping drugs at MDA 2026, a pivotal moment for patients and the company.

A key partnership ensures the supply of a breakthrough therapy for FOP, a devastating condition where muscle turns to bone, highlighting a new era in drug production.